Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Commodity, Ex-Dividend Stocks Weigh On FTSE 100

Thu, 18th Feb 2016 17:05

LONDON (Alliance News) - Shares in the London ended mixed Thursday, with commodity stocks and several hefty constituents going ex-dividend weighing on the FTSE 100, amid a flurry of economic data from China, Europe and the US.

The FTSE 100 ended down 1.0% at 5,971.95 points, ending in the red for the first time this week after a strong run in the past four sessions. The FTSE 250 closed up 0.1% at 16,176.75 and the AIM All-Share up 0.7% at 682.54.

In Europe the CAC 40 in Paris ended up 0.2% and the DAX 30 in Frankfurt closed up 0.9%.

Stocks in New York were lower at the London close, with the Dow Jones Industrial Average down 0.2%, the S&P 500 down 0.3% and the Nasdaq Composite down 0.6%.

First-time claims for US unemployment benefits unexpectedly decreased in the week ended February 14, according to a report released by the US Labor Department. The report said initial jobless claims fell to 262,000 from 269,000 the prior week, the lowest level since the week ended November 22. The drop surprised economists, who had expected jobless claims to rise to 275,000.

The report said continuing claims, a reading on the number of people receiving ongoing unemployment assistance, rose by 30,000 to 2.273 million in the week ended February 7.

The US Conference Board released a report showing a modest decrease by its index of leading US economic indicators in January, driven primarily by steep drops in stock prices and weakness in initial jobless claims. The Conference Board said its leading economic index declined by 0.2% in January following a revised 0.3% decrease in December. The modest drop by the index matched economist estimates.

Meanwhile, a report from the Federal Reserve Bank of Philadelphia revealed a modest increase by its index of regional manufacturing activity in February, but the index remained negative for the sixth consecutive month. The Philadelphia Fed said the diffusion index for current activity rose to a negative 2.8 in February from a negative 3.5 in January. A negative reading indicates continued weakness in business conditions. Economists had expected the index to inch up to a negative 3.0.

At the London close, the pound was slightly higher against the dollar. Sterling was quoted at USD1.4331, having stood at USD1.4328 at the close on Wednesday.

The euro was at USD1.1088 at the close, versus USD1.1133 at the close Wednesday.

The European Central Bank warned about "increased downside risks" in the minutes from its monetary policy meeting held January 21, released Thursday.

"Downside risks had increased again since the beginning of the current year, amid heightened uncertainty about the growth prospects of emerging market economies, volatility in financial markets and geopolitical risks," the minutes said.

The ECB minutes said that inflation had continued to be weaker-than-expected, mainly due to the renewed sharp fall in oil prices and the persistently subdued underlying price pressures.

Financial market conditions in the euro area had clearly deteriorated since the early December Governing Council meeting, although the magnitude and persistence of these developments were still uncertain, the report added.

The minutes also said that there was unanimity in the Governing Council in seeking a review of the policy stance in the next meeting on March 10 after a thorough analysis of data and also after receiving the latest ECB Staff macroeconomic projections.

Timo del Carpio, European Economist at RBC Capital markets said he saw little in the minutes that alters the more recent messages from various ECB officials.

"Looking ahead to March 10, a lively discussion on the macroeconomic outlook should again be expected. But with new staff projections and a firm commitment from the Governing Council to reconsider its stance, the Governing Council will have little excuse not to deliver a judgement on the appropriate policy stance the next time around," Del Carpio said.

Meanwhile, data from the ECB showed that the euro area current account surplus declined in December as the surplus on trade in goods and services dropped from the prior month. The current account surplus fell to EUR25.5 billion from EUR26.9 billion in November. The surplus on trade in goods dropped to EUR26.5 billion from EUR27.5 billion and that on services fell to EUR4.6 billion from EUR6 billion a month ago.

In Asia on Thursday, the Japanese Nikkei 225 index closed up 2.3%. The Shanghai Composite ended down 0.2% but the Hang Seng index in Hong Kong closed up 2.3%.

China's inflation accelerated to a five-month high in January, and the producer price index declined at a slower pace, data from the National Bureau of Statistics revealed.

Consumer prices advanced 1.8% year-on-year in January, faster than December's 1.6% increase. This was the highest rate since August 2015, when inflation was 2%, but slightly slower than the 1.9% rise forecast by economists. Producer prices dropped 5.3%, slower than the 5.9% decline seen in December. Prices were expected to fall 5.4%.

Data from the US Energy Information Administration showed that crude stockpiles in the US rose in the week ended February 12. The report said US crude oil inventories soared by 2.14 million barrels last week, compared to the decline of 754,000 barrels from the prior week. Economists expected an increase of 3.92 million barrels.

Following the data, North Sea benchmark Brent oil price dropped substantially, standing at USD34.34 a barrel at the London close, compared to USD35.34 prior. US benchmark West Texas Intermediate was also hit, falling to USD30.87 at the close versus USD31.65 before the data.

BP ended down 1.5%, while in the FTSE 250 Petrofac and Wood Group dropped 5.0% and 2.1%, respectively.

Meanwhile, shares in Tullow Oil ended at the bottom of the FTSE 250, down 11%. The oil and gas company said it has implemented extra "operational procedures" on the floating production, storage and offloading vessel serving the Jubilee field offshore Ghana after identifying an potential issue in the turret area.

Tullow said an inspection of the turret area of the FPSO was carried out by SOFEC, the original manufacturer of the turret, which identified "a potential issue" with the turret bearing.

Royal Dutch 'A' and 'B' shares ended down 3.2% and 2.2%, respectively, having gone ex-dividend alongside pharmaceutical giants GlaxoSmithKline, down 3.3%, and AstraZeneca, down 3.8%.

Shares in FTSE 100-listed mining companies were also sold, giving back some of their gains from Wednesday, with Anglo American down 4.7%, Rio Tinto down 3.1% and Glencore down 1.2%.

Gold was quoted at USD1,217.39 at the London close, adding to its impressive rally since the start of 2016.

At the other end of the index, gas distributor and producer Centrica led the blue-chip gainers, up 3.6%, after it reported full-year results that significantly beat expectations, as the drag on earnings from its upstream unit was not as bad as expected. Centrica reported a 4% fall in net earnings to GBP863.0 million in 2015 from GBP903.0 million in 2014, but the figure was significantly higher than analyst expectations of GBP733.0 million.

Adjusted operating cashflow, which Centrica said would be a "major focus" back in December, came in ahead of the group's guidance at GBP2.25 billion, which was also up 2% from GBP2.20 billion last year. Revenue for 2015 fell 5% to GBP28.00 billion. Centrica will pay a dividend for the year of 12.0 pence per share, down from 13.5 pence in 2014.

Following the results, Jefferies reiterated its Buy rating on Centrica, saying that the full-year results suggest the group's cash flow will remain strong in the current low commodity price environment.

BAE Systems also ended in the green, up 1.7%. The defence contractor provided a brighter outlook for 2016, as had been expected, indicating trading conditions for the group are starting to improve following years of squeezed defence budgets globally.

The defence contractor said its underlying earnings per share in 2016 should be around 5% to 10% higher than in 2015, helped by defence budgets increasing around the world and by growing sales in its cyber security and international sales, the latter of which should be boosted by higher Typhoon support service contract revenue.

This will offset declines in the US and UK, with the US set to see a reduction in naval ship repair activity, while UK sales will fall due to lower planned Typhoon deliveries, though higher submarine programme activity should help to offset falling aircraft carrier sales.

Drugmaker Indivior closed up 16%, making it the best FTSE 250 performer, as investors welcomed full year results from the group, which beat its previously lifted guidance, despite profit about halving in 2015 and the company saying it does not plan to pay further dividends in the "forseeable future".

Indivior has seen a better-than-expected first year as a public company following its spin-out from consumer goods giant Reckitt Benckiser Group in late 2014, despite the higher costs of operating on a standalone basis and increasing generic competition to its key product, Suboxone Film.

Indivior said its pretax profit for the year to the end of December was USD285.0 million, down from USD561.0 million a year earlier. It will pay a final dividend of 9.5 cents per share, taking its total dividend to 12.7 cents.

Transport company Go-Ahead Group closed up 6.0% after it said its first-half results met its expectations and affirmed its outlook for the full year as it saw solid performances in its bus and rail divisions. Pretax profit for the half-year to December 26 was GBP52.1 million, up from GBP44.7 million a year earlier, helped by a big rise in profit from its rail division. Go-Ahead will pay an interim dividend of 28.33 pence per share, up from 26.60p a year earlier.

Shore Capital upgraded the stock to Buy from Hold. The broker noted the company's shares have fallen by 16% year-to-date, giving them an attractive set of multiple and yield metrics.

In the corporate calendar, Coca-Cola HBC, Standard Life, M&C Saatchi, Segro, Essentra and Millennium & Copthorne Hotels release full-year results.

In the economic calendar Friday, Japan's All Industry Activity Index is due at 0330 GMT, while Germany's Producer Price Index is due at 0700 GMT. UK's Retail Sales data are at 0930 GMT, at the same time as UK Public Sector Net Borrowing data. The UK CB Leading economic index is due at 1430 GMT, while eurozone's consumer confidence is at 1500 GMT. In the US, inflation data are due at 1330 GMT.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.